Señales en vivo de LLY | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 may 2024 @ 16:00):

Stats
Volumen de hoy	2.38M
Volumen promedio	2.72M
Capitalización de mercado	771.28B
EPS	$0 ( 2024-04-30 )
Próxima fecha de ganancias	( $2.65 ) 2024-08-13
Last Dividend	$1.300 ( 2024-05-15 )
Next Dividend	$0 ( N/A )
P/E	119.52
ATR14	$0.525 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-28	Lilly Endowment Inc	Sell	2 052	Common Stock
2024-05-24	Lilly Endowment Inc	Sell	92 563	Common Stock
2024-05-23	Lilly Endowment Inc	Sell	6 061	Common Stock
2024-05-23	Lilly Endowment Inc	Sell	4 886	Common Stock
2024-05-23	Lilly Endowment Inc	Sell	3 491	Common Stock

INSIDER POWER
-64.92
Last 100 transactions
Buy: 132 023 \| Sell: 565 773

Volumen Correlación

Largo: 0.54 (weak)

Corto: 0.39 (neutral)

Signal:(52.767) Neutral

Eli Lilly and Co Correlación

10 Correlaciones Más Positivas
SBXC	0.96
HAFN	0.948
BAH	0.941
POST	0.94
BRK-B	0.936
IHTA	0.935
PHD	0.935
APO	0.933
FRTY	0.932
BRK-A	0.927

10 Correlaciones Más Negativas
NVVE	-0.936
BYON	-0.927
FNGD	-0.922
QBTS	-0.92
SRFM	-0.918
RIV-PA	-0.915
RTO	-0.915
EP-PC	-0.91
WDS	-0.907
CCG	-0.907

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eli Lilly and Co Correlación - Moneda/Commodity

0.44
( neutral )

0.32
( neutral )

0.00
( neutral )

0.42
( neutral )

0.38
( neutral )

-0.35
( neutral )

Eli Lilly and Co Finanzas

Annual	2023
Ingresos:	$34.12B
Beneficio Bruto:	$27.55B (80.73 %)
EPS:	$5.82

FY	2023
Ingresos:	$34.12B
Beneficio Bruto:	$27.55B (80.73 %)
EPS:	$5.82

FY	2022
Ingresos:	$28.54B
Beneficio Bruto:	$21.91B (76.77 %)
EPS:	$6.93

FY	2021
Ingresos:	$28.32B
Beneficio Bruto:	$21.01B (74.18 %)
EPS:	$6.15

Financial Reports:

No articles found.

Eli Lilly and Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.980 (N/A)	$0.980 (N/A)	$1.130 (N/A)	$1.130 (N/A)	$2.26 (N/A)	$1.130 (N/A)	$1.300 (N/A)	$1.300 (N/A)	$0 (N/A)	$0 (N/A)

Eli Lilly and Co Dividend Information - Dividend King

Dividend Sustainability Score: 7.30 - good (72.96%) | Divividend Growth Potential Score: 6.18 - Stable (23.63%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0114	1972-08-07
Last Dividend	$1.300	2024-05-15
Next Dividend	$0	N/A
Payout Date	2024-06-10
Next Payout Date	N/A
# dividends	209	--
Total Paid Out	$63.28	--
Avg. Dividend % Per Year	1.27%	--
Score	5.03	--
Div. Sustainability Score	7.30
Div.Growth Potential Score	6.18
Div. Directional Score	6.74	--

Next Divdend (Est)
(2024-07-01)

$1.314 Estimate 74.85 %

Dividend Stability

1.00 Excellent

Dividend Score

5.03

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.0228	0.56%
1973	$0.0494	1.00%
1974	$0.0606	1.32%
1975	$0.0688	1.64%
1976	$0.0782	2.44%
1977	$0.0888	3.01%
1978	$0.103	4.37%
1979	$0.122	4.06%
1980	$0.137	3.79%
1981	$0.144	3.64%
1982	$0.162	4.67%
1983	$0.172	4.79%
1984	$0.186	5.00%
1985	$0.200	4.94%
1986	$0.225	3.28%
1987	$0.250	2.69%
1988	$0.288	2.88%
1989	$0.337	3.15%
1990	$0.412	2.40%
1991	$0.500	2.75%
1992	$0.552	2.60%
1993	$0.604	3.94%
1994	$0.624	4.20%
1995	$0.654	4.01%
1996	$0.684	2.47%
1997	$0.740	2.04%
1998	$0.800	1.16%
1999	$0.920	1.07%
2000	$1.040	1.59%
2001	$1.120	1.22%
2002	$1.240	1.58%
2003	$1.340	2.05%
2004	$1.420	1.99%
2005	$1.520	2.70%
2006	$1.600	2.79%
2007	$1.700	3.25%
2008	$1.880	3.58%
2009	$1.960	4.83%
2010	$1.960	5.47%
2011	$1.960	5.60%
2012	$1.960	4.69%
2013	$1.960	3.96%
2014	$1.960	3.86%
2015	$2.00	2.85%
2016	$2.04	2.46%
2017	$2.08	2.79%
2018	$2.25	2.66%
2019	$2.58	2.25%
2020	$2.96	2.24%
2021	$3.40	2.05%
2022	$3.92	1.44%
2023	$5.65	1.55%
2024	$2.60	0.44%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend King	2023-06-30	Quarterly	2	5.23%	8.53
ACV	Dividend Royal	2024-06-13	Monthly	10	10.19%	8.50
ARR	Dividend Royal	2024-05-14	Monthly	15	11.08%	8.50
PVL	Dividend Royal	2023-11-15	Monthly	14	9.37%	8.50
ACP	Dividend Royal	2024-05-22	Monthly	14	11.88%	8.50
AVK	Dividend Royal	2024-05-14	Monthly	22	9.54%	8.31
AFG	Dividend Royal	2024-04-12	Bi-Monthly	39	9.39%	8.06
JPT	Dividend King	2023-11-02	Monthly	8	4.19%	8.05
VCIF	Dividend Royal	2023-08-18	Monthly	6	8.05%	8.02
EDI	Dividend Royal	2023-12-07	Monthly	13	8.85%	7.94

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.171	1.500	6.58	9.88	[0 - 0.5]
returnOnAssetsTTM	0.0960	1.200	6.80	8.16	[0 - 0.3]
returnOnEquityTTM	0.535	1.500	5.16	7.74	[0.1 - 1]
payoutRatioTTM	0.688	-1.000	3.12	-3.12	[0 - 1]
currentRatioTTM	1.354	0.800	8.23	6.58	[1 - 3]
quickRatioTTM	0.677	0.800	-0.721	-0.577	[0.8 - 2.5]
cashRatioTTM	0.132	1.500	-0.376	-0.564	[0.2 - 2]
debtRatioTTM	0.410	-1.500	3.17	-4.75	[0 - 0.6]
interestCoverageTTM	17.51	1.000	4.62	4.62	[3 - 30]
operatingCashFlowPerShareTTM	4.08	2.00	8.64	10.00	[0 - 30]
freeCashFlowPerShareTTM	-4.22	2.00	-2.11	-4.22	[0 - 20]
debtEquityRatioTTM	2.05	-1.500	1.817	-2.73	[0 - 2.5]
grossProfitMarginTTM	0.809	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.230	1.000	7.39	7.39	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.140	1.000	-0.332	-0.332	[0.2 - 2]
assetTurnoverTTM	0.562	0.800	9.59	7.67	[0.5 - 2]
Total Score				7.30

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	118.55	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.535	2.50	6.89	7.74	[0.1 - 1.5]
freeCashFlowPerShareTTM	-4.22	2.00	-1.406	-4.22	[0 - 30]
dividendYielPercentageTTM	0.602	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.08	2.00	8.64	10.00	[0 - 30]
payoutRatioTTM	0.688	1.500	3.12	-3.12	[0 - 1]
pegRatioTTM	10.38	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.102	1.000	9.94	0	[0.1 - 0.5]
Total Score				6.18

Eli Lilly and Co Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.